This study is looking into a new treatment for people receiving a kidney transplant from a sibling. The goal is to help your body accept the new kidney better and potentially allow you to stop taking immunosuppressant medicines. After your kidney transplant, you would receive a drug called rabbit anti-thymocyte globulin (rATG) and radiation to your lymph nodes and spleen (total lymphoid irradiation, or TLI). This is followed by an infusion of blood stem cells (CD34+ and CD3+ cells) from the same sibling who donated your kidney. Researchers will measure if you can stop immunosuppressive drugs 12 months after your kidney transplant. The study is for adults aged 18 and older who are getting a kidney from an HLA-identical sibling at UCLA Medical Center. This study is currently recruiting about 15 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 15 participants.

What's involved

You would need to live within a 3-hour drive of UCLA Medical Center for the first three to six months. The study will monitor your kidney function, measure cells in your blood, and take biopsies of your kidney at different times.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured 12 months after the kidney transplant. The study will also monitor graft function at serial time points.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.